Life Transitions

PH80 nasal spray shows promise in reducing menopausal hot flashes, offering an effective and safe non-hormonal treatment option.

At the 2024 Annual Meeting of The Menopause Society, the positive safety and efficacy data of fezolinetant against sleep disturbances from the SKYLIGHT 1 and 2 trials was presented.

A new study presented at the 2024 Annual Meeting of The Menopause Society shows hormone therapy remains beneficial for women over 65, helping manage menopause symptoms like hot flashes and improving quality of life.

A new study presented at the 2024 Annual Meeting of the Menopause Society found cognitive behavioral therapy can effectively address sexual concerns during menopause, improving overall well-being.

Female veterans with PTSD are twice as likely to experience early menopause and related health risks, according to a study presented at the 2024 Annual Meeting of The Menopause Society.

In a recent study presented at the 2024 Annual Meeting of The Menopause Society, 59% of nocturnal hot flashes occurred during the second half of the night, a time linked to increased cardiovascular disease risk.

A study presented at the 2024 Annual Meeting of The Menopause Society, found that women who reported physical intimate partner violence also demonstrated decreased working memory performance over time.

A significant connection has been identified between severe menopause symptoms and cognitive impairment in postmenopausal women, according to findings from a study published in Menopause, the journal of The Menopause Society.

A JAMA Pediatrics study found 37% of adolescents with gender dysphoria began hormone therapy within 2 years, highlighting barriers and inequities in care.

A recent study found that women with a shorter reproductive lifespan had increased odds of multimorbidity compared to those with a longer reproductive lifespan, indicating a need to assess reproductive factors to determine high-risk patients.

A recent study found that implementing postpartum transition support significantly boosts primary care engagement and reduces readmissions for chronic conditions.

A recent highlights elevated morbidity and mortality risks in premenopausal women underusing estrogen therapy after oophorectomy, underscoring the critical need for hormone therapy to mitigate adverse health outcomes.

A new study recently published in Menopause, the journal of The Menopause Society, suggests a significant link between chronic kidney disease (CKD) and tooth loss, particularly in postmenopausal women.

Though studies on the prevalence of depression during menopause vary, for those experiencing the symptoms, quality of life can be severely compromised.

A recent regression model analysis unveils a 5% prolonged period to menopause in women with polycystic ovary syndrome, prompting further investigation into the condition's impact on reproductive health and the need for diverse longitudinal studies.

Participants with poor sleep quality were 85% more likely to have poor cognitive performance on the Stroop test than participants with good sleep quality, a new study found.

This lecture, presented by Holly J. Pederson, MD, at The Menopause Society 2023 Annual Meeting, looked at combined oral contraceptives in BRCA carriers and other high-risk patients, and hormone therapy in postmenopausal gene carriers as well as other high-risk women.

The most recommended and non-recommended methods of nonhormone therapy for treatment of vasomotor symptoms were discussed at The Menopause Society 2023 Annual Conference.

Advancements in technology used to measure bone health in postmenopausal women were discussed at the Menopause Society 2023 Annual Meeting.

A recent study measuring sexual functioning in women with post-traumatic stress disorder was discussed at The Menopause Society 2023 Annual Meeting.

In a recent study highlighted at the Menopause Society 2023 Annual Meeting, a correlation was found between the number of hot flashes experienced and the risk of Alzheimer’s disease among perimenopausal and postmenopausal women.

A correlation between brown adipose tissue activity and hot flashes was discussed at the Menopause Society 2023 Annual Conference.

In a recent study, increased use of cannabis to manage menopause symptoms was observed among midlife women.

In a recent study highlighted at The Menopause Society 2023 Annual Meeting, White women with a psychiatric condition were 40% more likely to receive a hormone therapy prescription than Black women.

At The Menopause Society 2023 Annual Meeting, tips on reducing weight during menopause will be discussed.

The presence of NAFLD increased from 25.3% to 29.4% among patients receiving oral menopause hormone therapy.

In a recent study, women with premenstrual disorders were more likely to experience early menopause and vasomotor symptoms.

Menopausal women who drink alcohol should limit consumption to moderate drinking, according to experts. However, binge drinking in this population has been on the rise, for which clinicians can help by referring these patients to appropriate treatment.

Genevieve Neal-Perry, MD, PhD, talks about the recent approval of fezolinetant (Veozah; Astellas Pharma) and her latest phase 3 research presented at the 2023 ACOG Annual Clinical and Scientific Meeting.

Fezolinetant (Veozah; Astellas Pharma) is now the first neurokinin 3 receptor antagonist approved for the treatment of vasomotor symptoms associated with menopause.